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ABSTRACT
Aberrant activation of Janus kinase-3 (Jak3) and its key down-stream 
effectors, Signal Transducer and Activator of Transcription-3 (STAT3) and STAT5, 
is a key feature of malignant transformation in cutaneous T-cell lymphoma (CTCL). 
However, it remains only partially understood how Jak3/STAT activation promotes 
lymphomagenesis. Recently, non-coding microRNAs (miRNAs) have been implicated in 
the pathogenesis of this malignancy. Here, we show that (i) malignant T cells display 
a decreased expression of a tumor suppressor miRNA, miR-22, when compared to 
non-malignant T cells, (ii) STAT5 binds the promoter of the miR-22 host gene, and (iii) 
inhibition of Jak3, STAT3, and STAT5 triggers increased expression of pri-miR-22 and 
miR-22. Curcumin, a nutrient with anti-Jak3 activity and histone deacetylase inhibitors 
(HDACi) also trigger increased expression of pri-miR-22 and miR-22. Transfection of 
malignant T cells with recombinant miR-22 inhibits the expression of validated miR-
22 targets including NCoA1, a transcriptional co-activator in others cancers, as well 
as HDAC6, MAX, MYCBP, PTEN, and CDK2, which have all been implicated in CTCL 
pathogenesis. In conclusion, we provide the first evidence that de-regulated Jak3/
STAT3/STAT5 signalling in CTCL cells represses the expression of the gene encoding 
miR-22, a novel tumor suppressor miRNA. 
INTRODUCTION
Cutaneous T-Cell lymphoma (CTCL) is 
characterized by the proliferation of malignant T cells 
in a chronic inflammatory microenvironment. The 
etiology of CTCL remains only partially understood 
and, unfortunately, it has not been possible to identify 
one unifying genetic event or one particular oncogene of 
central importance for the malignant transformation and 
cancer progression. Instead, deregulation of signaling 
pathways including Signal Transducers and Activators of 
Transcription (STAT), src kinases, c-Myc, COX-2, NFκB, 
GATA3, TOX, and embryonic stem cell regulators appears 
to play an important role in the pathogenesis [1-11]. In 
particular, the Interleukin-2 receptor common gamma 
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chain (IL-2Rgc), the associated Janus kinase-3 (Jak3), 
and the down-stream effectors (STAT3 and STAT5) have 
attracted substantial interest in this regard. Indeed, the 
IL-2Rgc-signaling cytokines IL-2, IL-4, IL-7, IL-15, 
and IL-21 are implicated in early pathogenesis whereas 
constitutive, interleukin-independent activation of the 
Jak3/STAT3 pathway is believed to play a key role in 
progressive and advanced disease [12-15]. The aberrant 
activation of the Jak3/STAT pathway and interleukin-
independent proliferation of malignant T cells appears 
to be in part a result of deficient expression and/or 
function of negative regulators such as Suppressors Of 
Cytokine Signaling-3 (SOCS3) and the protein tyrosine 
phosphatases (e.g. SHP1) [16-18]. Importantly, the Jak3/
STAT pathway (i) promotes the expression of IL-5, IL-10, 
IL-17A, IL-17F cytokines, (ii) regulates the production 
of angiogenetic factors, and (iii) confers resistance to 
treatment with HDAC inhibitors in malignant T cells [19, 
7, 15, 20-24]. Yet, relatively little is known about STAT 
target genes in CTCL and how STAT3, STAT5, and their 
co-activators and/or co-repressors regulate of expression 
of disease-associated genes. 
Recently, a new class of post-transcriptional 
regulators, non-coding microRNAs (miRNAs), has 
received considerable attention in relation to CTCL. Skin 
lesions from CTCL patients displayed a distinct miRNA 
expression signature. Furthermore, a minimal miRNA 
classifier consisting of only three miRNAs (miR-155, 
miR-203, and miR-205) was able to distinguish between 
malignant and benign dermatoses with high accuracy 
suggesting that miRNAs profiling is a powerful diagnostic 
tool in CTCL[25-27]. Importantly, expression of several 
miRNAs including miR-155 and miR-21 were associated 
with progressive disease and a poor prognosis [27-31]. 
miR-21 confers resistance to apoptosis, while miR-155 
promotes malignant proliferation [14, 29]. Conversely, 
the expression of other miRNAs is often lost in CTCL 
skin lesions when compared to benign dermatoses and 
normal skin [25, 28, 30]. Some of these miRNAs are now 
recognized to act as tumor suppressors as documented by 
their ability to inhibit tumor growth and/or metastasis [32, 
33]. mir-22 expression is down-regulated in a number of 
cancers and has been assigned a role of tumor suppressor 
miRNA in colon and breast cancers [33-37]. In a recent 
study of miRNA expression in Sézary syndrome, a 
leukemic variant of CTCL, Ballabio et al. described a loss 
of miR-22 expression in circulating CD4+ T cells [38].
It is largely unknown what promotes the expression 
of onco-miRNAs and repression of tumor-suppressor 
miRNAs in CTCL. In the current work, we demonstrate 
that malignant T cells display down-regulation of miR-22 
expression and provide mechanistic evidence that Jak3/
STAT signaling inhibits the expression of this gene. This, 
in turn, contributes to elevated expression of MYCBP and 
MAX (co-activators of the c-Myc oncogene), and NCoA1, 
a transcriptional regulator previously associated with 
neoplastic transformation events [34]. Our work provides 
evidence that aberrant Jak3/STAT activation represses a 
novel tumor suppressor miRNA in CTCL.
RESULTS
Loss of miR-22 expression in malignant T cells
Decreased expression of miR-22 was recently 
reported in several solid cancers and in circulating CD4+ 
T cells in Sézary syndrome[35-39]. As shown in Figure 
1A, miR-22 expression was significantly downregulated 
in malignant CTCL T cell lines (MyLa2000, MyLa2059, 
SeAx, and PB2B) when compared to non-malignant (i.e. 
reactive) T cell lines obtained from CTCL skin lesions 
(MyLa1850 and MySi) and psoriatic skin (PSOR). 
Figure 1: Expression of mature and primary miR-22 in CTCL as determined by qPCR. a. miR-22 expression in non-
malignant (MyLa1850, MySi) and malignant (MyLa2000, MyLa2059, SeAx, PB2B) CTCL T cell lines as well as one T cell line derived 
from psoriasis vulgaris patient (PSOR), reference U6, n = 3. b. primary miR-22 (pri-miR-22) expression in non-malignant (MyLa1850) and 
malignant (MyLa2059) CTCL T-cell line. Reference GAPDH, n = 3 c. pri-miR-22 expression in primary Peripheral Blood Mononuclear 
Cells (PBMCs) derived from two healthy donors relative to one patient diagnosed with Sézary Syndrome, reference GAPDH. 
Oncotarget20557www.impactjournals.com/oncotarget
Notably, the expression of pri-miR-22 was also decreased 
in the malignant T cell line MyLa2059 when compared 
to non-malignant T- cell line (Figure 1B). Similarly in 
Sézary syndrome peripheral mononuclear cells miR-22 
expression was decreased when compared to the cells 
from healthy volunteers (Figure 1C). 
Jak3/STAT signaling represses miR-22 expression
Il-2Rg-signaling cytokines regulate expression of 
multiple miRNAs through the Jak/STAT pathway. As 
shown in Figure 2, IL-2 induced a significant decrease 
in miR-22 expression in non-malignant T cell lines 
MyLa1850 (Figure 2, left panel) and MySi (Figure 2, 
right panel). Conversely, inhibition of IL-2R signaling by 
Figure 2: Effect of the T cell growth factor, IL-2, on miR-22 expression. Expression of miR-22 in IL-2 sensitive, non-malignant, 
CTCL T cells (MyLa1850 and MySi). Cells were depleted of IL-2 for 48 hours (– IL-2) or depleted of IL-2 for 24 hours, followed by 24 
hours of IL-2 supplementation (+ IL-2). miR-22 expression was determined by qPCR using U6 as a reference n = 3. 
Figure 3: Curcumin treatment increases expression of mature and primary miR-22. miR-22 a. and pri-miR-22 b. expression 
measured by qPCR in non-malignant (MyLa1850) and malignant (MyLa2059, SeAx) CTCL T cells subjected to 24h treatment with 20µM 
curcumin or DMSO (control).a. Reference U6, n = 2. b. Reference GAPDH, error bars reflect variation in technical triplicates.
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curcumin (a broad-range Janus kinase inhibitor) triggered 
in IL-2 treated non-malignant T cells an increased miR-22 
expression when compared to the vehicle control (Figure 
3A, left). Likewise, in malignant T cells that are known 
display a constitutive, aberrant Jak3 activation [40], 
curcumin produced an up-regulation of miR-22 (Figure 
3A, right).. Notably, curcumin also enhanced pri-miR-22 
expression in malignant MyLa2059 and SeAx T cells 
(Figure 3B, right and central panels) and in IL-2-treated 
non-malignant T cells (Figure 3B, left panel). Since 
curcumin inhibits other kinases in addition to Jak3 in 
malignant T cells, we tested the effect of a more selective 
Jak inhibitor, Jak3- inhibitor II, on miR-22 expression in 
malignant T cells. As shown in Figure 4, Jak3- inhibitor 
II triggered an increase in miR-22 expression comparable 
to the effect of curcumin in an earler experiment (Figure 
3). Overall, these findings indicate that Jak3 activation 
repress miR-22 expression in malignant T cells. Since 
the active Jak3 mediates tyrosine phosphorylation and 
subsequent activation of STAT3 and STAT5 [1-3, 40], we 
examined whether Jak3-mediated repression of miR-22 
was regulated via these transcription factors. Figure 5A 
shows expression changes in miR-22 (Figure 5A) and 
STAT3, STAT5A, and STAT5b (Figure 5B) following 
siRNA-mediated depletion of these STATs in malignant T 
cells. Inhibition of STAT3, STAT5A, and STAT5B induced 
a significant increase in the expression of miR22 (Figure 
5A) Indicating that Jak3 regulates the expression of miR-
22 via both STAT3 and STAT5. 
STAT binding to the miR-22 host gene promoter
In addition to their role as transcriptional activators, 
STAT3 can also function as repressors of transcription. 
Thus, in some cancer models STAT3 represses the 
expression of multiple genes including key regulators 
of stress responses and neoplastic transformation such 
as p53 [41]. Interestingly, STAT3 has been implicated 
in both transcriptional activation and repression of the 
oncomiR-21[29, 42, 43], which probably reflects a cell-
context dependent recruitment of co-activators and co-
repressors such as BLIMP-1[43]. Likewise, STAT5 can 
function as a transcriptional activator or a transcriptional 
repressor [44-47]. Accordingly, we examined whether 
siRNA- mediated depletion of STAT3 and STAT5 
influenced the expression of the primary transcript of 
the miR-22 gene (miR-22HG/C17Orf91), pri-miR-22. 
As shown in Figure 6A, siRNA-mediated inhibition 
of STAT3, STAT5A, and STAT5B triggered increased 
expression of pri-miR-22 suggesting that they - directly or 
indirectly - repress transcription of miR-22HG. 
To elucidate whether STAT3 and STAT5 directly 
bind to the miR-22HG, we performed oligo-nucleotide-
based binding assay using a synthetic oligonucleotide 
corresponding to a STAT binding sequence in the miR-
22HG. As shown in Figure 6C, pY-STAT5 and to a lesser 
extend pY-STAT3 co-precipitated with the miR-22HG 
oligonucleotide. Notably, the phosphorylation of STAT3 
and STAT5 was almost completely blocked by pre-
Figure 4: Inhibition of JAK3 increases expression of mature miR-22 in malignant CTCL cell line MyLa2059. miR-22 
expression in MyLa2059 following 24 hours treatment with Jak3iII (40ug/mL) or DMSO control. Measured by qPCR, reference U6, n = 3.
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treatment of malignant T cells with a Jak3 inhibitor, CP-
690550, (Figure 6C, left panel). Since this inhibitor blocks 
STAT3 and STAT5 tyrosine phosphorylation (Figure 6C, 
left) and transcriptional activity[48], these findings suggest 
that the activated form of the STAT proteins bind to miR-
22HG. 
To address further whether STAT proteins 
directly bind the miR-22HG promoter in malignant T 
cells, we performed Chromatin Immune-Precipitation 
followed by DNA sequencing (ChIP-seq) to identify 
transcriptional targets of STAT and other putative relevant 
transcription factors in a more physiological setting. 
ChIP-seq analysis of STAT5-precipitated chromatin from 
malignant MyLa2059 cells yielded an enrichment of 
reads comprising a promotor region of the miR-22HG 
(C17Orf91, Figure 6D). In contrast, only few reads for 
the miR-22HG promoter were detected in chromatin 
precipitated with STAT3 antibody (Figure 6D). Since 
curcumin also inhibits NFκB signaling[49], we also 
performed chromatin immunoprecipitation with RelA and 
RelB antibodies. As shown in Figure 6D, precipitation 
with RelA and RelB antibodies did not yield any reads for 
the miR-22HG promoter region. 
Based on the information obtained from ChIP-seq, 
we designed primers flanking the STAT-binding site within 
the promoter (Supplementary Figure S1). These were used 
in an independent ChIP experiment to detect enrichment 
by PCR amplification of this sequence in chromatin from 
malignant MyLa2059 cells precipitated with STAT3 and 
STAT5 antibodies relative to a negative control antibody 
(rabbit IgG). Consistent with our earlier experiemental 
findings, ChIP-seq, PCR amplification (Figure 6E) showed 
a marked enrichment of the sequence representing the 
miR-22HG promoter in samples precipitated with STAT5 
antibody, whereas STAT3-precipitated samples produced 
a less pronounced band. In a parallel experiment, we 
observed enrichment of the sequence representing the 
STAT5 binding site in the BIC promoter in samples 
precipitated with STAT5 antibody whereas STAT3-
precipitated samples were negative (Figure 6E, lower 
panel) showing the specificity of the ChIP assay and 
confirming previous data on a selective STAT5 binding to 
the BIC promoter [14]. Taken together these data indicate 
that STAT5, and seemingly to a lesser degree, STAT3 bind 
to the miR-22HG promoter. 
HDAC inhibitors induce expression of miR-22 in 
malignant T cells
In addition to a direct transcriptional repression 
of target genes, STAT3 and STAT5 may also repress 
transcription through the recruitment of transcriptional co-
repressors such as EZH2 and HDACs [44, 46]. Hence, we 
treated malignant T cells with corresponding inhibitors to 
address whether repression of pri-miR-22 expression was 
mediated through these co- repressors. While the inhibitor 
of EZH2 (DZ-Nep) had no effect on pri-miR-22 expression 
at concentrations up to 10 µΜ uM (Supplementary Figure 
S2), a broad HDAC inhibitor, SAHA, used clinically for 
the treatment of CTCL, triggered a profound, time- and 
concentration- dependent up-regulation of pri-miR-22 
expression (Figure 7). These findings indicate that HDACs 
play a key role in pri-miR-22 repression, whereas EZH2 
most likely do not.. 
Figure 5: Transient knockdown of STAT3 and STAT5 genes increases expression of mature miR-22 in malignant CTCL 
cell line, Myla2059. a. miR-22 expression in MyLa2059 48h following transient transfection with siSTAT3, siSTAT5a, siSTAT5b or 
non-target (NT) control. Reference U6, n = 3, error bars reflect variation in technical triplicates. b. Representative Western Blot showing 
knockdown efficiency of siRNA transfections, 48h. 
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Figure 6: Binding of STAT transcription factors to the the miR-22HG C17orf91 and upstream promoter regions. a. 
primary miR-22 expression in MyLa2059 24h following transient transfection with siSTAT3, siSTAT5a, siSTAT5b or non-target (NT) 
control. Reference GAPDH, error bars reflect variation in technical triplicates. b. Knockdown efficiency is evaluated by Western Blot. c. 
Binding of p(y)STAT3 and p(y)STAT5 to an oligonucleotide sequence designed to mimic a putative STAT binding side inside the miR-
22HG, C17orf91. Malignant CTCL cell line, Myla2059, was treated for 24h with JAK inhibitor, CP690550 (50µM), DMSO or untreated 
(control). Protein extracts were subjected to oligonucleotide pulldown and investigated for p(y)STAT3 and p(y)STAT5 presence by Western 
Blotting before (input) and after (IP) pulldown. d. ChIP-seq reads from the C17orf91 promoter region in malignant MyLa2059 cells. Reads 
obtained from immunoprecipitation with STAT5, STAT3, RelB, RelA and a negative control (Rabbit IgG, bottom). The chromosomal 
position of C17orf91 and upstream WDR81 refer to hg19. Forward reads are indicated in green and reverse reads are shown in red. e. PCR 
analysis of ChIP samples using the primer set indicated in Supplementary Figure 1. For the C17orf91 promoter the 120bp amplicon was 
detected in the STAT5- and to a lesser degree the STAT3-precipitated samples. For the BIC (miR-155HG) promoter 190bp amplicon was 
detected only in the STAT5-precipitated sample. 
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Elucidating miR-22 targets in malignant T cells
miR-22 has been assigned a role of a tumor 
suppressor in various solid tumors (reviewed in [38]) 
as well as some hematological malignancies (acute 
lymphoblastic leukemia, multiple myeloma and anaplastic 
large cell lymphoma) [50-53]. While the molecular 
mechanisms of this miRNA have not been fully elucidated, 
several miR-22 targets have been identified and validated. 
Several these targets including HDACs and transcriptional 
co-activators/regulators of c-Myc [37,39,54,55] could 
be involved in the pathogenesis of CTCL. To determine 
whether these proteins were susceptible to inhibition by 
miR-22 in malignant T cells, we used electroporation to 
transfect these cells with a synthetic miR-22 (miR-22 
mimic). As shown in Figure 8, transfection with a miR-
22 mimic inhibited to various degree the expression of all 
seven verified miR-22 targets examined when compared to 
transfection with scrambled miR-22 serving as a negative 
control (Figure 8A). Accordingly, a marked inhibition 
by 30-60% of MAX, MYCBP, NCoA1, and PTEN was 
observed in both the malignant T cell lines analyzed: 
MyLa2059 and SeAx (Figure 8A). Other verified miR-22 
targets (CDK6, HDAC4 and HDAC6 [39, 56, 57]) were 
also inhibited by miR-22 but the effect was much weaker 
(Figure 8A). 
The profound inhibition of NCoA1 by miR-22 
is of particular interest as NCoA1 is a transcriptional 
co-activator regulating multiple oncogenic pathways 
associated with disease progression and metastasis 
formation in breast and prostate cancer [34]. When 
correlating miR-22 and NCoA1 expression in malignant 
and non-malignant T cells by RT-qPCR (Figure 8B), 
a relatively high miR-22 expression was associated 
with a low NCoA1 expression in non-malignant T cells 
and conversely a relatively low miR-22 expression in 
malignant T cells was associated with a high expression 
of NCoA1 mRNA (Figure 8B). These NCoA1 expression 
levels were also confirmed on a protein level (Figure 8C). 
To further substantiate and extend these findings, we 
transfected malignant T cell lines with a miR-22 mimic 
and a scrambled control miRNA and measured the miR-22 
effect on NCoA1 protein expression. As shown in Figure 
8D, miR-22 triggered a significant decrease in NCoA1 
protein expression therefore, supporting the notion that 
miR-22 directly down-regulates the expression of NCoA1 
in malignant T cells.
DISCUSSION
miR-22 has recently been assigned the role of a 
tumor suppressor miRNA and low expression has been 
reported in advanced disease and metastasis in several 
solid cancers (reviewed in [38]). In this work, we provide 
mechanistic evidence of deficient expression and putative 
tumor suppressive function of miR-22 in malignant T 
cells. Our data confirm and extend the recent findings by 
Ballabio et al. on down-regulation of miR-22 expression 
in peripheral blood malignant (Sézary) CD4+ T cells[58]. 
Our experimental molecular studies indicate that 
the observed low expression of miR-22 in CTCL was 
due to constitutive repression of miR-22 transcription 
by aberrant Jak3/STAT signaling in malignant T cells. 
Figure 7: HDAC inhibitor, SAHA, induces time- and concentration-dependent increase in primary miR-22 expression. 
Malignant CTCL cell line, MyLa2059, was treated for 0, 6 or 24 hours with 2µM or 15 µM SAHA or DMSO control. Relative expression 
of pri-miR-22 was determined by qPCR, reference GAPDH. Error bars reflect variation in technical triplicates
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We document that STAT5 and to a lesser extend STAT3 
bind to a STAT-binding motif in the miR-22HG promoter 
and down-regulate this gene. Thus, inhibition of the Jak3, 
STAT5A, and STAT5B and STAT3 led to up-regulation of 
pri-miR-22 and miR-22. We further document that HDAC 
inhibitors play an important role in regulating miR-22 
expression. Most importantly, our results demonstrate 
that forced expression of miR-22 in malignant cell lines 
inhibits expression of a number of critical oncogenes 
including MAX, MYCBP, NCoA1, and CDK6.
It is now well established that in addition to their 
function as transcription factors, STAT5 and STAT3 can 
function as transcriptional repressors. For instance STAT5 
represses the expression of Cyclin D2 and BCL6 [47, 59], 
Figure 8: Expression of previously verified miR-22 targets are decreased by miR-22 mimic in malignant CTCL cell 
lines. a. Expression of CDK6, HDAC4, HDAC6, MYX, MYCBP, NCoA1 and PTEN following transient transfection with miR-22 mimic 
relative to a scrambled control in malignant CTCL cell lines (MyLa2059, SeAx) as determined by qPCR. Reference GAPDH, n = 7. b. 
qPCR comparison of relative NCoA1-(left panel) and pri-miR-22-(right panel) mRNA expression levels in malignant versus non-malignant 
cell lines (upper panel: MyLa2059 vs. MyLa1850, lower panel: SeAx vs. MyLa1850). Reference GAPDH, n = 3 c. Western Blot showing 
NCoA1 protein expression levels in non-malignant (MyLa1850) and malignant (MyLa2059, SeAx) CTCL cell lines. d. Relative expression 
of NCoA1 protein in malignant CTCL cells (left: MyLa2059, right: SeAx) following transfection with miR-22 mimic or scrambled control. 
Upper inset is a representative of the Western Blots results for NCoA1 and GAPDH quantification, n = 3.
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whereas STAT3 represses Glucose-6-Phosphatase and p53 
expression [41, 60]. However, relatively little is known 
about the mechanisms involved in STAT3 and STAT5- 
mediated repression of gene transcription. Steric hindrance 
by STAT proteins and recruitment of other co-repressors 
might account for their function as transcriptional 
repressors (reviewed in [61]). Thus, STAT5 inhibits 
expression of the Ig kappa light chain locus by recruiting 
EZH2, which in turn triggers histone-trimethylation and 
chromatin conformational changes [42, 44, 62]. 
Likewise, STAT3 and STAT5 recruit HDACs which, 
depending on the cellular context, repress or activate 
transcription through de-acetylation of STAT proteins 
and other molecules in the transcriptional complexes. 
An inhibitor of EZHs had no effect on the expression 
of pri-miR-22, whereas inhibitors of HDACs induced a 
profound up-regulation in miR-22 expression suggesting 
that HDACs, but not EZHs, might be involved in the 
repression of pri-miR-22 transcription.
To assess a putative regulatory function of miR-22 
in malignant T cells, we evaluated expression changes of 
validated miR-22 targets. Specifically, we investigated 
the effect of miR-22 on the expression of NCoA1, MAX, 
MYCBP, HDAC4, HDAC6, CDK6, and PTEN, all of 
which have independently been validated as miR-22 
targets [37, 39, 54-57, 63, 64]. Constitutive expression 
of miR-22 inhibited all of these targets. Four targets 
(NCoA1, MAX, MYCBP, and PTEN) demonstrated a very 
high sensitivity to miR-22- mediated inhibition, whereas 
the other targets were only weakly inhibited by miR-22. 
The inhibition of MAX and MYCBP was of particular 
relevance because they have previously been proposed to 
play a pathogenic role in CTCL due to their effect on the 
C-Myc oncogene [19, 64, 65]. 
We, therefore, propose a model where miR-22 
expression is low in malignant T cells and is down 
regulated by IL-2 in normal T cells, while MAX and 
MYCBP are constitutively active in malignant T cells 
and are activated by IL-2Rgc cytokines in non-malignant 
T cells [64]. Therefore, we believe that the repression of 
miR-22 by IL-2Rgc cytokines and Jak3/STAT activation 
is not only relevant in relation to CTCL, but might have 
implications for T cell biology in general.
NCoA1, also known as the steroid receptor co-
activator (SRC-1), is a transcriptional co-activator and 
repressor not previously described in lymphoma but 
linked to oncogenesis in malignancies such as carcinoma 
of breast, ovarian, and prostate (reviewed by Walsh [34]). 
Indeed, global gene repression by NCoA1 promotes 
oncogenesis and metastatic spread in breast cancer [66, 
67]. Interestingly, the major clinical importance of an 
increased expression of NCoA1 in patients with advanced 
cancer relates to the development of drug resistance [68-
71]. For instance, NCoA1 protects cancer cells from 
tamoxifen induced apoptosis [66, 72]. In malignant T 
cells, as demonstrated in our study, constitutive expression 
of miR-22 inhibited NCoA1 expression on mRNA and 
protein levels, confirming its role in regulating NCoA1 
expression and function [73]. As NCoA1 regulates 
retinoid signaling and several other nuclear receptors in 
addition to the steroid receptor, studies are in progress to 
address whether NCoA1 plays a role in drug resistance in 
CTCL and whether co-transfection of miR-22 potentiates 
the efficacy of anti-cancer therapies and drugs such as 
bexarotene and tazarotene and other treatment modalities. 
Indeed, in a study on the efficacy of extracorporeal 
photochemotherapy (ECP) in CTCL, Berger et al. 
[74] reported on a dramatic effect on leukocyte gene 
expression. The study did not include information of miR-
22 expression but analysis of the raw microarray data-
set obtained from NCBI (GSE23604) (Supplementary 
Figure 3S (A-C)) indicates that a subset of miR-22 target 
genes (74 genes) were significantly altered following 
ECP ( > 2 fold change, p < 0.001) (Suppl. Figure S3D). 
These included validated miR-22 targets (NCoA1 and 
PTEN) examined in the current study, which were both 
significantly inhibited post-ECP (Suppl. Figure S3E). 
These data indicate that NCoA1 and other miR-22 target- 
genes are inhibited following ECP suggesting a potential 
role of miR-22 target genes, and by inference restoration 
of miR-22, in mediating the effect of ECP [74]. 
Recent data in mice demonstrated that locked 
nucleotide acid (LNA)-modified oligonucleotides have 
promising therapeutic potentials and are now tested 
in a phase one clinical trial [75]. Since LNA-modified 
oligonucleotides can be designed to mimic both miR-
agonists and antagonists, it may be speculated that LNA-
based miR-22 mimics might also have a therapeutic 
potential in cancer treatment.
In conclusion, we demonstrate for the first time, 
that miR-22 expression is down-regulated in CTCL 
malignant T cells and propose a molecular mechanism, 
where aberrant Jak3/STAT signaling leads to STAT3/
STAT5 activation and binding to its cognate sequence 
on the miR-22HG promoter. This binding leads to a 
direct transcriptional repression of the gene. We further 
demonstrate that normal function of this tumor suppressor 
microRNA is to down-regulate a number of putative 
oncogenes including validated miR-22 targets MAX, 
MYCBP, HDAC4, HDAC6, CDK6, and NCoA1. Taken 
together, these findings suggest that Jak3/STAT-mediated 
repression of miR-22 plays a key role in the pathogenesis 
and progression of CTCL. Combined with other reports, 
our results indicate that the Jak3-STAT3/STAT5 pathway 
may serve as therapeutic targets in CTCL.
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MATERIALS AND METHODS
Cell lines and culture
Malignant T cell lines, MyLa2059, MyLa2000, 
PB2B and SeAx were established from patients diagnosed 
with CTCL [75, 76]. MyLa1850 and MySi are non-
malignant T cell lines that were also established from 
CTCL patients [77]. PSOR2 is a non-malignant cell line 
established from a patient with psoriasis vulgaris [78]. 
All cell lines were cultured in RPMI1640 medium 
(#R2405, Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 5% penicillin/streptomycin (Sigma-
Aldrich). Furthermore the medium used for MyLa2059, 
MyLa2000 and PB2B was supplemented with 10% fetal 
bovine serum (Life Technologies, Roskilde, Denmark). 
The medium used for SeAx, MyLa1850, MySi and 
PSOR2 was supplemented with 10% human serum (Blood 
Bank, State University Hospital, Copenhagen, Denmark) 
and 103U/mL IL-2 (Proleukin) (Chiron, Emeryville, CA, 
USA) and 25ng/mL IL-4 (Leinco, St. Louis, MO, USA) 
(the latter only for PSOR2). Peripheral blood mononuclear 
cells (PBMCs) were isolated from a patient diagnosed 
with CTCL as well as from two healthy donors using a 
Ficoll Gradient, Lymphoprep (Axis-Shield PoC AS, Oslo, 
Norway) and were described elsewhere [79].
Inhibitors
JAK inhibitor II (Calbiochem, San Diego, CA, 
USA); JAK3 inhibitor, CP690550 (Pfizer, Ballerup, 
Denmark); Curcumin (Alexis, Laufelfigen, Switzerland); 
SAHA (Vorinostat) (Cayman Chemical, Ann Arbor, MI, 
USA); Trichostatin A, MS-275 (Entinostat) and Sodium 
Butyrate (Enzo Life Sciences, Plymouth Meeting, PA, 
USA); DzNep hydrochloride (Sigma-Aldrich). 
Antibodies
Antibodies used in this work are commercially 
available and were obtained as follows: NCOA1 antibody 
from LifeSpan Bioscience (Seattle, WA, USA) (LS-
B1702). pySTAT3 antibody from Nanotools (Denzlingen, 
Germany) (#0036-100/STAT3-9E12). STAT5a and 
STAT5b antibodies from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA) (L-20, SC-1081; C-17, sc-835-G). py-
STAT5, STAT5, STAT3, RelA, RelB, Histone H3 and 
rabbit IgG antibodies from Cell Signaling Technologies 
(Beverly, MA, USA) (#9351, #9358, #4904, #8242, 
#4922, #4620, #2729). GAPDH antibody from Abcam 
(Cambridge, UK) (Ab9485) ; and β- Actin antibody from 
Sigma-Aldrich (A4700). 
Oligonucleotide pulldown assay
Biotinylated oligonucleotides were designed 
complementary to the predicted STAT binding 
site (according to the transcription factor search 
database TFSEARCH version 1.3 http://www.
cbrc.jp/papia/howtouse/howtouse_tfsearch.html 
inside C17orf91/miR-22HG (forward: 5’BIO- 
TCACTCTTCAGGGAAAAGTGATA-3’; reverse: 
5’BIO-TATCACTTTTCCCTGAAGAGTGA- 3’) and 
were synthesized by Eurofins MWG GmbH (Martinsried, 
Germany). Lyophilized Ooligonucleotides were 
resuspended in nuclease-free water and annealed at 95°C 
for 5 min. Samples were lysed, and the supernatant was 
pre-cleared with streptavidin agarose beads (Invitrogen, 
Paisley, UK) for 3h rotating at 4°C. The supernatant was 
transferred to a new tube and agarose beads as well as 
250 pmol oligos per sample were added. Samples were 
incubated overnight rotating at 4°C. After being washed 5 
times with lysis buffer, sample loading buffer was added; 
the samples were denatured at 100°C for 10 min and 
subsequently subjected to SDS-PAGE and blotted for pY-
STAT3 and pY-STAT5.
Chromatin Immunoprecipitation (ChIP) was 
performed using SimpleChIP® Enzymatic Chromatin IP 
kit (Agarose Beads) from Cell Signaling Technologies 
(Beverly, MA, USA) as previously described [14]. 
Cross-linked chromatin fragments were captured with 
antibodies against STAT3, STAT5, RELA, RELB, Histone 
H3 (positive control) or rabbit IgG (negative control). 
PCR was performed on immunoprecipitated and control 
DNA samples using primers for regions upstream of the 
promoters C17orf91 (miR-22HG) (forward sequence: 
5`TCC TAA AGA GCA GGC GAA AG3`; reverse 
sequence: 5`AAA AAT GCC AAC TCA CAG AGC3` ) 
and BIC (miR-155HG) (forward sequence: 5` GAA AGG 
GAA AGG GGA AAA CA3`; reverse sequence: 5` CGA 
ACG TGC GAC CCT TTT AT3`) respectively. Both sets 
of primers were designed to encompass putative STAT 
binding sites. PCR annealing temperature was 56ᵒC and 
amplicon sizes were 120bp and 190bp for miR-22HG- and 
miR-155HG genes, respectively. The PCR products were 
separated on a 3% agarose gel using ethidium bromide for 
visualization. 
ChIPseq library construction and sequencing was 
described in detail in Kopp et al. [14].
Transient transfections
2*106 cells per sample were transfected with small 
interfering RNA (siRNA) against JAK3, STAT3, STAT5a, 
STAT5b or non-targeting control #1 (ON-TARGETplus 
SMARTpool, Thermo Scientific, Lafayette, CO, USA). 
Cell pellets were resuspended in 100uL transfection 
solution (Ingenio Electroporation solution, Mirus Bio, 
Oncotarget20565www.impactjournals.com/oncotarget
Madison, WI, USA) with 0.5 nmol of the respective 
siRNAs and transfected with an Amaxa Nucleofector 
(Amaxa GmbH, Cologne, Germany).
For transient transfection with microRNA mimic 
(agomiR), 7*106 cells/sample were transfected with 0.25 
nmol miR-hsa-miR-22-3p mimic or mimic control (both 
miRVana® miRNA mimics, Ambion (Sigma-Aldrich, Saint 
Louis, MO, USA). For SeAx cells a single transfection 
was performed whereas MyLa2059 cells were subjected 
to transfections on two consecutive days. 
Protein extraction and western blotting
Protein was extracted from 1*106 cells persample 
and subjected to SDS-PAGE and Western blotting as 
described previously [79], [80].
RNA extraction and qRT-PCR
Total RNA was purified with miR-Neasy Mini Kit 
(Qiagen, Valencia, CA, USA), cDNA was transcribed from 
10ng RNA using TaqMan® miRNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA, USA). Real-
time PCR was performed using TaqMan® miRNA assays 
(Applied Biosystems, Foster City, CA, USA) for miR-22 
(#000398) according to the manufacturer’s instructions. 
Expression of U6 (#001973) was used as a reference. 
For quantification of expression of pri-miR-22 or various 
mRNAs, RNA extraction was performed with the RNeasy 
Mini Kit (Qiagen, Valencia, CA, USA). cDNA was 
subsequently transcribed using the High Capacity cDNA 
Reverse Transcription Kit followed by PCR analysis 
using TaqMan® Gene Expression Assays: pri-miR-22 
(#Hs03302632_pri), NCOA1 (#Hs00186661), CDK6 (Hs 
01026371_m1), HDAC4 (Hs 01041638_m1), HDAC6 
(Hs 00195869_m1), MAX (Hs 00811069_g1), MYCBP 
(Hs 00429315_g1), PTEN (Hs 02621230_s1) (all from 
Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s instructions. GAPDH (#Hs02758991_
g1) was included as a reference. The amplification was 
performed on an Mx3005P qPCR System (Agilent 
Technologies, Santa Clara, CA, USA) real-time cycler on 
standard settings. 
Statistics
For statistical analysis a two-tailed Student’s 
t-test with a significance level of p = 0.05 was used. A 
significant difference (p < 0.05) between a sample and 
control is indicated with an asterisk.
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